Swiss Med-Tech Firm to Move Some Output Abroad to Ease Tariffs

Swiss medical-devices maker Ypsomed Holding AG plans to move some production to Germany and ramp up output in the US due to the threat of 39% tariffs on imports from Switzerland, according to Chief Executive Officer Simon Michel.

Ypsomed, which is valued at 5.3 billion francs ($6.6 billion), is one of the first publicly traded companies to disclose concrete steps to offset US President Donald Trump’s latest decision on tariffs targeting Swiss goods.

The Burgdorf, Switzerland-based maker of self-injection systems is forging ahead with plans to move half of Swiss production destined for the US to facilities in ...